Article Text

Download PDFPDF
Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate
  1. S E Papapoulos1,
  2. R C Schimmer2
  1. 1Department of Endocrinology and Metabolic Diseases, Leiden University Medical Centre, Leiden, The Netherlands
  2. 2Department of Endocrinology and Metabolic Diseases, F Hoffmann-La Roche Ltd, Basel, Switzerland
  1. Correspondence to:
    Dr S E Papapoulos
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands; M.V.Iken{at}


Bisphosphonates reduce the rate of bone resorption and bone remodelling. Given daily, they decrease the risk of fractures in postmenopausal osteoporosis. When bisphosphonates were given at extended drug-free intervals this antifracture efficacy was generally not seen. This may be due to the different pattern of bone remodelling changes. Data from randomised clinical studies of ibandronate, given orally or intravenously, at different doses and for variable time intervals to women with osteoporosis were examined to explore the relationship between intermittent bisphosphonate therapy, changes in bone resorption and fracture risk. The magnitude of the reduction of the rate of bone resorption at the end of the drug-free interval rather than its fluctuation pattern after bisphosphonate administration determines antifracture efficacy, provided that these fluctuations occur within the premenopausal range. Prolongation of the drug-free interval beyond 2 weeks should be compensated by a dose higher than the cumulative daily dose.

  • BMD, bone mineral density
  • IV, intravenous
  • bisphosphonates
  • bone resorption
  • fractures
  • ibandronate
  • osteoporosis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Published Online First 2 February 2007

  • Dr Papapoulos has received research funding from MSD and Procter & Gamble and has served as consultant for MSD, Novartis, Procter & Gamble and Roche/GSK. Dr Schimmer is an employee of Roche.